Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Scholar Rock received FDA approval for ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children aged 2 and older. This marks the first and only muscle-targeted treatment approved for SMA, representing a significant therapeutic breakthrough for the company's myostatin biology platform.
Earnings call
Sep 14, 2026, 8:00 AM ET
“Today’s FDA approval of ISEMBYLD marks a defining moment for the SMA community as we now launch the world’s first-ever muscle targeted treatment for children and adults living with SMA in the U.S. After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough with ISEMBYLD.”
David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock
AirJoule Technologies Signs $27M M&A Deal with Bitsink LLC
AirJoule Technologies acquired 100% of Bitsink LLC, a manufacturer of cooling and power infrastructure for AI and high-density data centers, for $18 million in cash and $9 million in common stock. The deal includes up to $40 million in additional performance-based earnout payments through 2029, significantly expanding AirJoule's footprint in the AI and HPC infrastructure market.
Texas Capital Bancshares Nasdaq/NYSE Compliance Notice
Texas Capital Bancshares is voluntarily withdrawing its common and preferred stock listings from Nasdaq to transfer them to the newly formed Texas Stock Exchange (TXSE). Trading is expected to begin on the TXSE on October 8, 2026, with a subsequent ticker symbol change from TCBI to TXCP scheduled for November 9, 2026.
Cullinan Therapeutics and Taiho announced positive results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation-positive NSCLC. The trial met its primary endpoint, showing a statistically significant median progression-free survival of 14.5 months compared to 8.5 months for chemotherapy alone (HR 0.50).
Armata Pharmaceuticals received FDA Breakthrough Therapy designation for its AP-SA02 product candidate for the treatment of complicated S. aureus bacteremia. The designation is supported by Phase 2 data showing a 100% clinical response rate without relapse at 28 days, compared to 75% for the placebo group. This status is intended to expedite the development and review of the therapy, which could potentially become the first antibacterial treatment approved based on superiority to current standard-of-care.
Corbus Pharmaceuticals Holdings Clinical Trial Data
Corbus Pharmaceuticals announced positive topline results from its CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The study met its primary objectives, demonstrating statistically significant weight loss of 5% at the 60 mg dose over 12 weeks with a favorable safety profile and no evidence of weight loss plateauing. The data supports CRB-913's potential as a first-in-class oral, non-incretin obesity medicine.
Hain Celestial Group Divestiture to Aurelius for $323M
Hain Celestial has entered into a definitive agreement to sell its International business operating in the UK, Ireland, and Europe to affiliates of private equity firm AURELIUS for approximately $323.2 million (£238.5 million). The transaction includes brands such as Ella’s Kitchen, Joya, and Hartley’s, with net proceeds intended to reduce the company's indebtedness. Closing is contingent on regulatory approvals and an amendment to the company's credit agreement to extend its December 2026 maturity date.
Value
$323M
Counterparty
AURELIUS
Earnings call
Sep 14, 2026, 8:00 AM ET
“Fiscal 2026 was a pivotal year for Hain. We simplified our portfolio, reduced debt, significantly improved free cash flow and exited the year with improving momentum across the business.”
Alison Lewis, President and CEO
“Assuming we successfully complete the transaction announced today to sell our International business and that we reach an agreement with our lenders to extend of our December debt maturity, we would expect to become a more focused North American company with leading brands in attractive categories and a streamlined operating model.”
Addentax Group Corp. entered into a private placement agreement with investor Chan Chun Hong to sell 520,834 shares of common stock at $4.80 per share. The transaction is expected to generate gross proceeds of approximately $2.5 million, which the company intends to use for general corporate purposes and strategic investments.
Perspective Therapeutics Research Collaboration with Merck
Perspective Therapeutics has entered into a clinical trial collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda. The combination will be tested in an ongoing Phase 1/2a study for FAP-alpha positive solid tumors, with Perspective sponsoring the study and Merck providing pembrolizumab at no cost.
Lipocine Inc. announced the initiation of BLOOM, a Phase 3 clinical study evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. The study aims to enroll approximately 120 participants with first dosing expected in early Q4 2026, following exploratory findings from a prior trial that suggested rapid symptom relief.
Artificial Intelligence Technology Solutions (AITX) announced that its RAD subsidiary has commercially launched the integration of its ROSA and RIO security platforms with the Immix monitoring ecosystem. The integration allows major guarding and monitoring companies to manage RAD's AI-driven security devices directly within their existing Immix workflows. The company is currently engaging with the nation's largest security providers for evaluation and deployment.
abrdn Global Infrastructure Income Fund Capital Raise
abrdn Global Infrastructure Income Fund (ASGI) has announced a transferable rights offering for its common shareholders of record as of September 21, 2026. Shareholders will receive one right for every share held, allowing them to subscribe for one new common share for every three rights at a subscription price equal to 92.5% of the average closing market price (or 92.5% of NAV if higher). The fund intends to use the additional capital to invest in global infrastructure assets across power, communications, and transportation sectors.
Rainier Acquisition Corporation announced that holders of units from its $86.25 million initial public offering may elect to separately trade the underlying Class A ordinary shares and warrants starting September 14, 2026. The separated securities will trade on Nasdaq under the symbols RNAQ and RNAQW, while unseparated units continue under RNAQU. The IPO, which included the full exercise of the over-allotment option, was led by Chardan Capital Markets.
Centrus Energy Corp. entered into an underwriting agreement for a public offering of 500,000 shares of Class A common stock, along with pre-funded and common warrants. The proceeds are intended for general corporate purposes, including technology deployment, debt repayment, and potential acquisitions. Guggenheim Securities and Barclays are serving as the book-running managers for the offering.
AIB Data Centers Signs $17.2M M&A Deal with Seller A and Seller B
AIB Data Centers Inc. completed the acquisition of approximately 29.385 acres of real property in Texas for $17.2 million to develop a new data center site. The transaction includes two interdependent agreements for adjacent properties with existing and planned primary electric service totaling 55 MW. The deal was structured as a cash purchase for Property A and a membership interest purchase for Property B, which includes a $6 million deferred payment.
Belden Inc. filed an amendment to its previous 8-K to provide required audited and pro forma financial statements following its completed acquisition of the RUCKUS reporting segment from Vistance Networks, Inc. The filing includes historical financial data for Ruckus Wireless Networks for 2024, 2025, and the first quarter of 2026 to satisfy SEC reporting requirements for a material acquisition.
Counterparty
Ruckus Wireless Networks (reporting segment of Vistance Networks, Inc.)
Greenwave Technology Solutions Capital Raise of $3.75M
Greenwave Technology Solutions closed a private placement of 3,750 shares of Series B Convertible Preferred Stock with five institutional investors. The preferred shares have a stated value of $1,000 per share and are convertible into common stock at an initial conversion price of $5.24 per share. The company filed a Certificate of Designations to authorize the issuance and define the rights of the new preferred securities.
KULR Technology Group sold its entire remaining holdings of 764 bitcoin through a series of open market transactions for gross proceeds of approximately $58.6 million. The sales were conducted as part of the company's treasury management operations at a weighted average price of $76,633 per BTC.
Banzai International entered into a securities purchase agreement for a private placement of convertible promissory notes and warrants with an accredited investor. The deal provides for up to $2.5 million in gross proceeds across three tranches, with $1.5 million funded at the initial closing. The notes carry a 30% original issue discount and are convertible into Class A common stock at a fixed price of $2.75 per share.
Brightline Interactive received a staff determination notice from Nasdaq on September 11, 2026, stating that its common stock is subject to delisting for failing to meet the $1.00 minimum bid price requirement. The company failed to regain compliance during the initial 180-day grace period that ended September 9, 2026. Brightline plans to appeal the decision by requesting a hearing before a Nasdaq Hearings Panel, which will stay the suspension of its stock pending a final decision.
Volato Group Signs $500M M&A Deal with Alignment Engine Inc.
Volato Group completed its acquisition of Alignment Engine Inc. (Aligned) on September 11, 2026, in a merger where Aligned securityholders received 95% of the post-closing company's Class A common stock. The transaction was based on an Aligned valuation of $500 million and included a 180-day lock-up period for the newly issued shares. The deal was approved by Volato's board following the receipt of a fairness opinion and did not require stockholder approval.